ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1480

Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region

Jamal Al-Saleh1, Faisal Elbadawi1, Rajaie Namas2, Samar Al-Emadi3, Khalid A. Alnaqbi4, Humaid A. Al-Wahshi5, Amjad Alkadi6, Suad Hannawi7, Mohamed Hamouda8, Averyan Vasylyev8, Arwa Al-Shujairi8, Reem Al-Jayyousi9 and Munther Khamashta8, 1Dubai Hospital, Department of Rheumatology, Dubai, United Arab Emirates, 2Cleveland Clinic Abu Dhabi, Department of Rheumatology, Abu Dhabi, United Arab Emirates, 3Hamad Medical Corporation, Department of Rheumatology, Doha, Qatar, 4Tawam Hospital, Department of Rheumatology, Al Ain, United Arab Emirates, 5The Royal Hospital, Department of Rheumatology, Muscat, Oman, 6Ministry of Health, Kuwait, Kuwait, 7Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, 8GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, 9Mohamed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, United Arab Emirates, and Mediclinic Parkview, Dubai, United Arab Emirates

Meeting: ACR Convergence 2023

Keywords: Comorbidity, health status, Lupus nephritis, Renal, SF36

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Data from limited studies of LN in the Gulf region suggest that LN manifests more severely in this region than in Caucasian populations, yet there are no treatment recommendations specific to the Gulf region.1 This study aims to characterize patients with LN in the Gulf region to better understand disease burden and inform treatment recommendations to improve patient outcomes.

Methods: In this prospective, multicenter study (GSK Study 216989), adults with an established diagnosis of LN (biopsy proven or clinician diagnosis) were enrolled from sites in Kuwait, Oman, Qatar, and the UAE. At enrollment, the site physician extracted patient demographics and clinical characteristics retrospectively from medical charts for the previous < 12 months, and patients completed the 36-Item Short Form Health Survey (SF-36). Prospective medical chart follow-up continued for up to 12 months after enrollment. This analysis reports only data collected retrospectively at enrollment.

Results: This analysis comprised 193 patients with LN, the majority of whom were female (83.9%), of Arab ethnicity (85.0%), and with a mean (standard deviation [SD]) age of 37.2 (10.4) years (Table). Patients had a mean (SD) age of 27.4 (10.6) years at the time of SLE diagnosis, 30.5 (10.8) at LN diagnosis, and 35.3 (9.9) at ESKD diagnosis (n=11). Comorbidities were reported for 69.4% (n=134) of patients, most commonly endocrine and metabolic disorders (32.1%; n=62). One-third of patients had no kidney biopsy in the year preceding enrollment (35.6%; n=68), and LN class was not available for 26.9% (n=52) of patients, suggesting a potential lack of routine biopsy for some patients. Among available data, the proportions of LN Class III, IV, and V were similar (22.0–25.5%; n=31–36). Renal remission was achieved any time after LN diagnosis in 57.7% (n=101) of patients with available data. The mean (SD) number of prior treatment failures/relapses was 1.4 (3.6) in those with available data. Mean (SD) overall SF-36 score was 66.3 (19.1); scores across domains were generally similar, with energy/fatigue having the lowest score (57.7 [21.2]), and social functioning the highest (72.6 [26.5]; Figure).

Conclusion: These retrospective data suggest that approximately one-quarter of patients with LN in the Gulf region did not have sufficient histological classification to guide therapy, and these inconsistencies in histological data make it difficult to compare Gulf patient characteristics to published data from international cohorts. However, age at SLE diagnosis was young, and patients appeared to be similarly impacted across all SF-36 quality of life subscales, whereas a large international inception cohort reported relatively greater impacts in role of physical functioning than other domains.2 Prospective data generated from this cohort may aid understanding of differences in care and may have the potential to inform LN treatment guideline development in the Gulf region.

Funding: GSK

References

  1. Al-Shujairi A et al. Lupus 2023;32:155–65
  2. Hanly JG et al. Rheumatology (Oxford) 2016;55(2):252–62

Supporting image 1

Table. Summary of demographics and characteristics among patients with LN in the Gulf region.

*Those reported for >10% of patients are shown; †for 11 of the 12 patients with ESKD; ‡percentage among those with available data (n=191); §percentage among those with classification (n=141) ‖percentage among those with available data (n=175); ¶data missing for 42 patients (n=151).
ISN/RPS, International Society of Nephrology and the Renal Pathology Society.

Supporting image 2

Figure. Mean (SD) SF_36 subscale scores (N=193).


Disclosures: J. Al-Saleh: Dubai Academic Health Service, 3, Sheikh Hamdan, 5; F. Elbadawi: GSK, 2; R. Namas: None; S. Al-Emadi: AbbVie, 2, 6, AstraZeneca, 2, 6, Johnson & Johnson, 2, 6; K. Alnaqbi: Tawam Hospital, SEHA Abu Dhabi, 3; H. Al-Wahshi: GSK, 2, Ministry of Health, Oman, 3; A. Alkadi: Sabah hospital-ministry of health-Kuwait, 3; S. Hannawi: GSK, 2, 6; M. Hamouda: GSK, 3; A. Vasylyev: GSK, 3, 11; A. Al-Shujairi: GSK, 3; R. Al-Jayyousi: GSK, 2, 6; M. Khamashta: GSK, 3, 11.

To cite this abstract in AMA style:

Al-Saleh J, Elbadawi F, Namas R, Al-Emadi S, Alnaqbi K, Al-Wahshi H, Alkadi A, Hannawi S, Hamouda M, Vasylyev A, Al-Shujairi A, Al-Jayyousi R, Khamashta M. Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/demographic-and-clinical-characteristics-of-patients-with-ln-a-multicenter-study-from-the-gulf-region/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/demographic-and-clinical-characteristics-of-patients-with-ln-a-multicenter-study-from-the-gulf-region/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology